Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Genie29jon May 03, 2023 1:45am
102 Views
Post# 35426714

RE:RE:On their MD&A that just came out

RE:RE:On their MD&A that just came out

I agree that if dialog is happening, this is a positive. If this is the case, I believe this is the result of Andrew & Jamie buying in...aka, showing strength because let's be honest, Shiseido has likely secretly been hoping Replicel goes bankrupt and they get away full and clear with RCH – 01 and owning nothing in return. Can you blame them? Especially under Lee's leadership? 

But as far as a partnership, Replicel has virtually no staff. So how would they partner together? What value would Replicel bring to the table? I personally believe Replicels plan all along is to simply sell RCH 01 rights outright and collect a huge payday. 

If it's a success, I hope they accept nothing less than $1B for global rights. Then Take that money and invest in the device and tendon make double 


Yours truly,
cautiously optimistic 

<< Previous
Bullboard Posts
Next >>